IMAB Total Current Liabilities vs Other Current Assets Analysis

IMAB Stock

USD 0.94 0.02 2.08%

I Mab financial indicator trend analysis is infinitely more than just investigating I Mab recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether I Mab is a good investment. Please check the relationship between I Mab Total Current Liabilities and its Other Current Assets accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in I Mab. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For information on how to trade IMAB Stock refer to our How to Trade IMAB Stock guide.

Total Current Liabilities vs Other Current Assets

Total Current Liabilities vs Other Current Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of I Mab Total Current Liabilities account and Other Current Assets. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between I Mab's Total Current Liabilities and Other Current Assets is 0.47. Overlapping area represents the amount of variation of Total Current Liabilities that can explain the historical movement of Other Current Assets in the same time period over historical financial statements of I Mab, assuming nothing else is changed. The correlation between historical values of I Mab's Total Current Liabilities and Other Current Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Liabilities of I Mab are associated (or correlated) with its Other Current Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Current Assets has no effect on the direction of Total Current Liabilities i.e., I Mab's Total Current Liabilities and Other Current Assets go up and down completely randomly.

Correlation Coefficient

0.47

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Total Current Liabilities

Total Current Liabilities is an item on I Mab balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of I Mab are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Other Current Assets

Assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories.

Most indicators from I Mab's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into I Mab current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in I Mab. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For information on how to trade IMAB Stock refer to our How to Trade IMAB Stock guide.At present, I Mab's Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 17.21, whereas Tax Provision is forecasted to decline to 0.00.

	2022	2023	2024 (projected)
Interest Expense	1.3K	101.9K	96.8K
Depreciation And Amortization	25.3M	23.9M	20.6M

Interest Expense Depreciation And Amortization

I Mab fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Long Term Debt	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Long Term Debt Total	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity
Total Assets		-0.81	0.86	0.85	0.89	0.84	0.62	-0.24	-0.98	-0.57	-0.43	0.89	0.82	-0.79	-0.81	0.99	0.74	-0.16	0.83	0.78	0.18	-0.77	-0.45	0.75	0.44	0.73
Short Long Term Debt Total	-0.81		-0.84	-0.83	-0.55	-0.87	-0.25	-0.23	0.86	0.85	0.63	-0.56	-0.41	0.65	0.92	-0.85	-0.36	0.63	-0.92	-0.89	0.19	0.9	0.35	-0.9	-0.04	-0.76
Other Current Liab	0.86	-0.84		1.0	0.64	0.72	0.65	-0.25	-0.89	-0.74	-0.63	0.76	0.58	-0.93	-0.91	0.88	0.6	-0.25	0.8	0.89	0.0	-0.89	-0.21	0.92	0.44	0.56
Total Current Liabilities	0.85	-0.83	1.0		0.6	0.68	0.66	-0.26	-0.87	-0.72	-0.57	0.75	0.56	-0.92	-0.92	0.87	0.59	-0.22	0.77	0.86	0.02	-0.9	-0.14	0.9	0.47	0.53
Total Stockholder Equity	0.89	-0.55	0.64	0.6		0.76	0.65	-0.35	-0.86	-0.33	-0.37	0.88	0.9	-0.67	-0.5	0.87	0.71	0.06	0.69	0.61	0.28	-0.42	-0.68	0.51	0.45	0.61
Net Tangible Assets	0.84	-0.87	0.72	0.68	0.76		0.4	0.24	-0.84	-0.81	-0.71	0.57	0.51	-0.55	-0.73	0.86	0.45	-0.56	0.98	0.89	0.13	-0.66	-0.75	0.8	-0.07	0.89
Property Plant And Equipment Net	0.62	-0.25	0.65	0.66	0.65	0.4		-0.63	-0.58	-0.33	-0.29	0.7	0.59	-0.72	-0.47	0.62	0.72	0.26	0.43	0.55	0.59	-0.42	-0.23	0.43	0.63	0.3
Current Deferred Revenue	-0.24	-0.23	-0.25	-0.26	-0.35	0.24	-0.63		0.22	-0.41	-0.25	-0.6	-0.6	0.54	0.01	-0.19	-0.51	-0.81	0.24	0.1	-0.19	0.01	-0.26	0.07	-0.94	0.36
Net Debt	-0.98	0.86	-0.89	-0.87	-0.86	-0.84	-0.58	0.22		0.61	0.46	-0.9	-0.78	0.82	0.86	-0.99	-0.66	0.21	-0.84	-0.82	-0.04	0.82	0.41	-0.78	-0.45	-0.68
Retained Earnings	-0.57	0.85	-0.74	-0.72	-0.33	-0.81	-0.33	-0.41	0.61		0.79	-0.26	-0.06	0.49	0.8	-0.64	-0.2	0.77	-0.89	-0.92	-0.03	0.78	0.39	-0.87	0.23	-0.74
Accounts Payable	-0.43	0.63	-0.63	-0.57	-0.37	-0.71	-0.29	-0.25	0.46	0.79		-0.2	-0.13	0.54	0.47	-0.46	-0.13	0.56	-0.75	-0.8	0.09	0.41	0.61	-0.82	0.23	-0.54
Cash	0.89	-0.56	0.76	0.75	0.88	0.57	0.7	-0.6	-0.9	-0.26	-0.2		0.91	-0.83	-0.64	0.88	0.71	0.23	0.55	0.57	0.1	-0.6	-0.27	0.51	0.76	0.38
Non Current Assets Total	0.82	-0.41	0.58	0.56	0.9	0.51	0.59	-0.6	-0.78	-0.06	-0.13	0.91		-0.71	-0.44	0.77	0.83	0.27	0.45	0.4	0.21	-0.39	-0.36	0.41	0.68	0.43
Non Currrent Assets Other	-0.79	0.65	-0.93	-0.92	-0.67	-0.55	-0.72	0.54	0.82	0.49	0.54	-0.83	-0.71		0.74	-0.79	-0.65	-0.04	-0.61	-0.73	0.03	0.71	0.15	-0.79	-0.67	-0.35
Long Term Debt	-0.81	0.92	-0.91	-0.92	-0.5	-0.73	-0.47	0.01	0.86	0.8	0.47	-0.64	-0.44	0.74		-0.85	-0.5	0.47	-0.82	-0.87	0.05	0.99	0.09	-0.86	-0.29	-0.65
Cash And Short Term Investments	0.99	-0.85	0.88	0.87	0.87	0.86	0.62	-0.19	-0.99	-0.64	-0.46	0.88	0.77	-0.79	-0.85		0.7	-0.22	0.87	0.83	0.16	-0.81	-0.45	0.78	0.41	0.74
Net Receivables	0.74	-0.36	0.6	0.59	0.71	0.45	0.72	-0.51	-0.66	-0.2	-0.13	0.71	0.83	-0.65	-0.5	0.7		0.11	0.46	0.46	0.57	-0.47	-0.22	0.47	0.56	0.57
Good Will	-0.16	0.63	-0.25	-0.22	0.06	-0.56	0.26	-0.81	0.21	0.77	0.56	0.23	0.27	-0.04	0.47	-0.22	0.11		-0.62	-0.57	0.16	0.46	0.3	-0.56	0.68	-0.66
Common Stock Total Equity	0.83	-0.92	0.8	0.77	0.69	0.98	0.43	0.24	-0.84	-0.89	-0.75	0.55	0.45	-0.61	-0.82	0.87	0.46	-0.62		0.95	0.11	-0.76	-0.63	0.88	-0.06	0.89
Common Stock Shares Outstanding	0.78	-0.89	0.89	0.86	0.61	0.89	0.55	0.1	-0.82	-0.92	-0.8	0.57	0.4	-0.73	-0.87	0.83	0.46	-0.57	0.95		0.07	-0.82	-0.48	0.93	0.07	0.76
Short Term Investments	0.18	0.19	0.0	0.02	0.28	0.13	0.59	-0.19	-0.04	-0.03	0.09	0.1	0.21	0.03	0.05	0.16	0.57	0.16	0.11	0.07		0.08	-0.26	-0.07	0.07	0.35
Long Term Debt Total	-0.77	0.9	-0.89	-0.9	-0.42	-0.66	-0.42	0.01	0.82	0.78	0.41	-0.6	-0.39	0.71	0.99	-0.81	-0.47	0.46	-0.76	-0.82	0.08		0.0	-0.84	-0.29	-0.6
Non Current Liabilities Total	-0.45	0.35	-0.21	-0.14	-0.68	-0.75	-0.23	-0.26	0.41	0.39	0.61	-0.27	-0.36	0.15	0.09	-0.45	-0.22	0.3	-0.63	-0.48	-0.26	0.0		-0.34	0.3	-0.65
Capital Surpluse	0.75	-0.9	0.92	0.9	0.51	0.8	0.43	0.07	-0.78	-0.87	-0.82	0.51	0.41	-0.79	-0.86	0.78	0.47	-0.56	0.88	0.93	-0.07	-0.84	-0.34		0.1	0.7
Other Current Assets	0.44	-0.04	0.44	0.47	0.45	-0.07	0.63	-0.94	-0.45	0.23	0.23	0.76	0.68	-0.67	-0.29	0.41	0.56	0.68	-0.06	0.07	0.07	-0.29	0.3	0.1		-0.22
Other Stockholder Equity	0.73	-0.76	0.56	0.53	0.61	0.89	0.3	0.36	-0.68	-0.74	-0.54	0.38	0.43	-0.35	-0.65	0.74	0.57	-0.66	0.89	0.76	0.35	-0.6	-0.65	0.7	-0.22

Click cells to compare fundamentals

I Mab Account Relationship Matchups

I Mab fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.7B	6.3B	5.6B	4.1B	2.6B	3.7B
Short Long Term Debt Total	132.5M	13.6M	112.5M	75.0M	18.9M	17.9M
Other Current Liab	531.7M	567.4M	593.3M	637.3M	371.9M	463.9M
Total Current Liabilities	588.5M	576.1M	624.0M	659.7M	411.8M	534.5M
Total Stockholder Equity	(2.0B)	5.6B	4.6B	3.0B	242.4M	230.3M
Other Liab	2.5M	3.9M	125.0M	335.8M	386.2M	405.5M
Net Tangible Assets	(1.3B)	(2.3B)	5.3B	4.3B	5.0B	5.2B
Property Plant And Equipment Net	46.5M	40.3M	158.5M	124.0M	11.7M	11.1M
Current Deferred Revenue	3.9M	7.5M	2.4M	8.7M	32.6M	34.2M
Net Debt	(1.0B)	(4.7B)	(3.4B)	(3.1B)	(2.0B)	(2.1B)
Retained Earnings	(2.5B)	(2.0B)	(4.4B)	(6.8B)	(8.3B)	(7.9B)
Accounts Payable	67.7M	(3.9M)	(2.4M)	(33.1M)	(29.8M)	(28.3M)
Cash	1.1B	4.8B	3.5B	3.2B	302.1M	287.0M
Non Current Assets Total	376.3M	990.1M	847.7M	447.2M	276.3M	262.5M
Non Currrent Assets Other	18.3M	2.0M	26.6M	10.9M	246.2M	258.5M
Other Assets	18.3M	2.0M	26.6M	237.3M	272.9M	286.6M
Cash And Short Term Investments	1.2B	4.8B	4.3B	3.4B	2.3B	2.9B
Net Receivables	55.9M	130.5M	286.9M	4.8M	18.0M	17.1M
Common Stock Shares Outstanding	57.8M	68.4M	76.0M	82.5M	83.2M	71.8M
Short Term Investments	32M	31.5M	753.2M	235.4M	143.2M	269.9M
Liabilities And Stockholders Equity	1.7B	6.3B	5.6B	4.1B	2.6B	3.7B
Non Current Liabilities Total	3.2B	130.5M	417.6M	405.6M	483.0M	458.8M
Capital Lease Obligations	14.3M	13.6M	112.5M	56.0M	45.0M	37.9M
Inventory	(55.9M)	(422.9M)	27.2M	(80.3M)	(18.0M)	(18.9M)
Other Current Assets	191.8M	195.5M	190.8M	172.5M	47.1M	44.8M
Other Stockholder Equity	(2.7B)	5.7B	9.1B	1.2B	8.3B	8.7B
Total Liab	3.8B	706.6M	1.0B	1.1B	894.8M	1.4B
Net Invested Capital	(1.9B)	5.6B	4.6B	3.0B	1.8B	1.9B
Property Plant And Equipment Gross	46.5M	40.3M	158.5M	124.0M	156.4M	90.5M
Total Current Assets	1.4B	5.3B	4.8B	3.6B	2.3B	3.2B
Accumulated Other Comprehensive Income	70.1M	(50.8M)	(186.5M)	216.7M	298.3M	313.2M
Net Working Capital	772.8M	4.8B	4.2B	3.0B	1.9B	2.6B
Short Term Debt	56.8M	(33.6M)	30.7M	22.4M	7.3M	7.0M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether I Mab offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of I Mab's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of I Mab Stock. Outlined below are crucial reports that will aid in making a well-informed decision on I Mab Stock:

How To Invest In IMAB

Details

Is IMAB Stock a good investment?

Details

What is I Mab's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in I Mab. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For information on how to trade IMAB Stock refer to our How to Trade IMAB Stock guide.

You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of I Mab. If investors know IMAB will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about I Mab listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.16)

Revenue Per Share

0.043

Quarterly Revenue Growth

(0.62)

Return On Assets

(0.29)

Return On Equity

(0.72)

The market value of I Mab is measured differently than its book value, which is the value of IMAB that is recorded on the company's balance sheet. Investors also form their own opinion of I Mab's value that differs from its market value or its book value, called intrinsic value, which is I Mab's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because I Mab's market value can be influenced by many factors that don't directly affect I Mab's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between I Mab's value and its price as these two are different measures arrived at by different means. Investors typically determine if I Mab is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, I Mab's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

IMAB Total Current Liabilities vs Other Current Assets Analysis

Total Current Liabilities vs Other Current Assets

Total Current Liabilities vs Other Current Assets Correlation Analysis

Correlation Coefficient

Total Current Liabilities

Other Current Assets

I Mab fundamental ratios Correlations

I Mab Account Relationship Matchups

High Positive Relationship

High Negative Relationship

I Mab fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Liabilities	+ 1.0	Other Current Liab
Cash And Short Term Investments	+ 0.99	Total Assets
Long Term Debt Total	+ 0.99	Long Term Debt
Common Stock Total Equity	+ 0.98	Net Tangible Assets
Common Stock Shares Outstanding	+ 0.95	Common Stock Total Equity
Capital Surpluse	+ 0.93	Common Stock Shares Outstanding

Cash And Short Term Investments	- 0.99	Net Debt
Net Debt	- 0.98	Total Assets
Other Current Assets	- 0.94	Current Deferred Revenue
Non Currrent Assets Other	- 0.93	Other Current Liab
Common Stock Shares Outstanding	- 0.92	Retained Earnings
Long Term Debt	- 0.92	Total Current Liabilities